TKI treatment failure is driving up the disease burden of CML
Normin Health just published a study leveraging the existing literature evidence addressing the disease burden of Chinese patients with chronic myeloid leukaemia (CML) who failed with the first and second generation tyrosine kinase inhibitors (TKI). Even though the wide use of imatinib, the first generation TKI, has substantially improved the survival prognosis in patients with CML, the rising patients with TKI treatment failure have become the major disease management challenge due to the lack of effective and safe treatments addressing the drug resistance of first and second generation TKI. The existing literature evidence suggested that the CML patients with TKI treatment failure were likely to have faster disease progression, reduced quality of life, poorer survival prognosis, and increased health resource utilization. Our study is a good case study using literature evidence to demonstrate the disease burden and address the unmet medical needs of patients. For more details about this publication, please click here.